Squamous-cell cancer of the head and neck (SCCHN) represents a heterogeneous disease entity, with various etiological factors implicated in the genesis of distinct molecular subsets of tumors, which exhibit different biological and clinical behavior. Treatment of SCCHN is expected to change in the next decade as targeted therapies continue to make strides. Recently, next-generation sequencing studies conducted on ∼190 SCCHN specimens shed light into the molecular pathogenesis of the disease. These studies discovered mutations in genes involved in the differentiation program of squamous epithelium and the Notch/p63 axis (such as NOTCH1, TP63 and FBXW7), and validated genetic alterations derived from previous studies (such as mutations in TP53, CDKN2A, PIK3CA, CCND1 and HRAS) as driver genetic events in SCCHN neoplastic transformation. More recently, comprehensive data from The Cancer Genome Atlas (TCGA) project on 306 SCCHN specimens provided further insight into SCCHN inherent molecular complexity, identifying novel significantly mutated genes, including FAT1, MLL2, TGFRBR2, HLA-A, NFE2l2 and CASP8. In this article, we provide an overview of the mutational spectrum of SCCHN, with emphasis on the clinical implementation of this knowledge. We also discuss the potential integration of new data within the framework of precision cancer medicine.
introduction Squamous-cell cancer of the head and neck (SCCHN) represents the sixth most common malignancy, with 650 000 new cases and 350 000 SCCHN-related deaths reported annually worldwide [1] . A number of 'traditional' clinicopathological parameters, such as the primary tumor site and the TNM stage are currently used to classify patients in terms of prognosis and to make therapeutic decisions. Tobacco and alcohol use have historically accounted for the vast majority of SCCHN cases. In the past decade, infection with high-risk human papilloma viruses (HPV) and especially serotype 16, has been implicated in the pathogenesis of a subset of SCCHN, especially those arising from the tonsillar oropharynx [2] .
A better understanding of the molecular pathogenesis of SCCHN, facilitated by advances in genomic and proteomic approaches, has led to the identification of molecular targets for therapy. A wide range of candidate biomarkers, including the epidermal growth factor receptor (EGFR), the nuclear factor kappa-light-chain enhancer of activated B cells (NFκB), the signal transducers and activators of transcription (STATs) and components of the Wnt/β-catenin, transforming growth factorbeta and phopshoinositide 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathways, have been reported as useful and potentially targetable diagnostic and prognostic molecular tools [3] . Despite advances in our knowledge on head and neck carcinogenesis and innovations in surgery, chemotherapy and radiation therapy, the survival rates for many types of SCCHN have not improved significantly over the past 40 years [4] . A deeper understanding of SCCHN carcinogenesis is needed to promote the development of novel therapeutic approaches.
Recently, further insight into the molecular progression model of SCCHN has been provided by four whole-exome sequencing studies conducted on ∼190 SCCHN specimens in total [5] [6] [7] [8] . These studies showed that SCCHN is characterized by a high degree of intertumor heterogeneity, further confirming the complexity of head and neck cancer biology. At the same time though, they revealed a small subset of cases with potentially targetable mutations, especially in HPV-positive tumors. More recently, whole-exome sequencing data from The Cancer Genome Atlas (TCGA) project [9] on 306 SCCHN specimens shed further light into this molecular complexity, identifying novel significantly mutated genes [10] . In this article, we describe the main findings of these studies with emphasis on the perspectives and challenges anticipated from the implementation of these results in clinical practice.
high-throughput sequencing and molecular classification of head and neck tumors Molecular-profile-directed treatment has been found feasible and of potential clinical benefit in patients with metastatic solid malignancies: A pilot study [11] in refractory metastatic tumors demonstrated clinical benefit, defined as progression-free survival (PFS) ratio (PFS on molecular-profile-directed treatment/ PFS on prior treatment) of ≥1.3 in 27% of patients who received tailored therapy [95% confidence interval (CI) 17% to 38%; one sided P = 0.007]. In nonsmall-cell lung cancer (NSCLC), several studies have revealed the feasibility of molecular profiling in the majority of patients and the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE-1) was the first prospective molecular-profile-directed trial in NSCLC [12] . At present, despite extensive research efforts, preclinical data have not been widely incorporated into the selection of patients or tailored treatment regimens in clinical trials of SCCHN. Recently, Walter et al. [13] used an integrated genomic analysis and validation methodology to confirm the presence of four, previously identified [14] molecular classes of SCCHN, namely the basal, mesenchymal, atypical and classical subtypes on the basis of genetic signatures, including the deregulation of the KEAP1/NFE2L2 oxidative stress pathway, the differential utilization of the lineage markers SOX2 and TP63 and the oncogene addiction for PIK3CA and EGFR [12] .
The use of high-throughput genome sequencing and mutational analysis provides an unprecedented opportunity for clinical implementation of an individualized therapeutic approach in SCCHN. Individual SCCHN harbors a set of genetic aberrations that can be informative for testing currently available targeted therapies. The selection of one driver gene mutation for therapy with a matching drug, however, is limited by feedback and cross-talk communications between signaling networks.
gene copy alterations and loss-offunction mutations deregulate the cellular network of tumor suppressor genes in SCCHN Data analysis from the four comprehensive, whole-exome sequencing studies in SCCHN [5] [6] [7] [8] revealed several common key findings that validated the dominant role of tumor suppressor pathways including TP53, CDKN2A and PTEN in disease pathogenesis, as suggested by previous molecular studies (reviewed in [15] ). These findings were further validated by results of the recently reported TCGA analysis, which also revealed a significant rate of mutations in previously unidentified genes, such as FAT1, MLL2, TGFRBR2, HLA-A, NFE2l2 and CASP8 [9] . Inactivating TP53 mutations, in particular, emerge as the dominant genetic event, with a mutational rate of 69.8% in the TCGA series (Table 1) . It is worth noting that functional inactivation of TP53 may also occur via other mechanisms, including overexpression or amplification of MDM2, which mediates p53 proteasomal degradation, and p53 protein degradation by the HPV E6 oncoprotein [16, 17] . TP53, the socalled guardian of the genome, is activated in response to DNA damage and can lead to cell cycle arrest, providing the necessary pause for the cell to attempt DNA repair [18] . The functional consequences of different mutations further complicate the system with some mutations completely disrupting DNAbinding capabilities while others allow TP53 to selectively interact with a subset of genes. Moreover, p53 exerts functional effects via direct protein-protein interactions with cell cycle regulatory proteins; Missense mutations, by altering the tertiary structure of p53 can modify these interactions and disrupt the function of the proteins. This effect is known as 'gain of function' and gain-of-function mutant TP53 can behave as a dominant oncogene and exert oncogenic properties [14, 19, 20] . Mutations in TP53 are detectable in early stages of tobaccoinduced carcinogenesis and are even present in premalignant dysplastic lesions [21, 22] . The incidence of these mutations in SCCHN associated with tobacco and alcohol use is almost double compared with nonsmokers [23, 24] . The presence of TP53 mutations is associated with poor clinical outcome and a recent analysis of 420 SCCHN cases using a hybridization approach with a TP53 chip, which carries all known mutations, showed a decline in survival by more than 1.5-fold in patients with disruptive TP53 mutations [25] . TP53 mutations have also been associated with poor response to chemotherapy and radiotherapy [26] [27] [28] [29] [30] . Skinner et al. [14] recently demonstrated that, in postsurgical patients with SCCHN treated with radiotherapy, disruptive TP53 mutations were associated with a higher risk for locoregional recurrence compared with nondisruptive ones. In addition, SCCHN patients whose tumors had histologically negative surgical margins and tested positive for a TP53 mutation were found to be associated with high risk for recurrence [31] .
Therapeutic strategies aiming at restoring wild-type p53 utilizing viral vectors have established safety in phase I trials [32] while multiple phase II studies [33, 34] have shown promising efficacy. A recent phase III study comparing adenovirus TP53 gene therapy, Advexin (Introgen, Inc., Austin, TX) to methotrexate for recurrent SCCHN showed that wild-type TP53 patients responded better to Advexin while patients with tumors containing mutant TP53 responded better to methotrexate [35] . It appears therefore that, in tumors containing low levels of wild-type p53, due to upregulation of MDM2, the combination of normal exogenous p53 delivered by gene therapy and low levels of endogenous p53 was sufficient to overcome this form of p53 inhibition. A TP53 adenoviral-based treatment of SCCHN, the drug ONYX-015 (Onyx Pharmaceuticals, Inc., San Francisco, CA) has been recently approved for SCCHN in China [36] .
The exome sequencing studies also confirmed that the retinoblastoma tumor suppressor pathway is frequently altered through deletion of CDKN2A ( p16) or amplification of cyclin D1 (CCND1), promoting thus cell proliferation ( Table 1 ). The p16 protein prevents phosphorylation of the retinoblastoma ( pRb) protein by binding to the cyclin D1 CDK4/CDK6 complex. These phosphorylated isoforms, in turn, release E2F transcription factors and subsequently activate transcription of genes involved in cell cycle progression such as cyclin A [9] ( Figure 1 ).
Of note, chromosomal deletion of the 9p region that contains the P16 (CDKN2A) gene locus was identified as the most frequent chromosomal alteration: ∼35% of analyzed samples were found to harbor deletions of the 9p21-22 gene loci. In addition to these chromosomal alterations, somatic mutations of CDKN2A are relatively frequent with a mutational rate of 21.3% based on TCGA data [10] . Besides genetic alterations, P16 inactivation frequently occurs via other mechanisms such as epigenetic silencing through promoter hypermethylation resulting in an incidence of P16 inactivation approaching 80% in SCCHN [37, 38] . Another major finding was that chromosomal deletions of the P16 are often associated with cyclin D1 gene amplification in SCCHN. Of note, mutations in CDKN2A and/or gene amplification of CCND1 were reported in 94% (33 of 35) assessable oral squamous-cell carcinomas (OSCC) in the study by Pickering et al. [8] rendering thus cell cycle alterations an appealing therapeutic target in this patient population. High p16 protein levels have been associated with favorable prognosis in oropharyngeal squamous-cell cancer [39] while high cyclin D1 protein level assessed with automated quantitative protein analysis has been linked to inferior outcome in OSCC [40] . It is unclear whether genetic alterations at the 9p21 locus, where P16 resides, are sufficient to induce carcinogenesis by themselves, as they have also been detected in benign epithelial lesions with low malignant potential [41] . On the other hand, lesions of oral leukoplakia containing loss of heterozygosity (LOH) at 9p had increased malignant potential [42, 43] . In vitro studies using the demethylating agent 5-azacitidine have shown restoration of p16 expression [44, 45] . p16 adenovirus approaches have been Table 1 . Comparison of the findings of the main large-scale exome sequencing studies [5] [6] [7] [8] 10] Stransky et al. [6] Agrawal et al. [7] Lui et al. [ 
the EGFR/MAPK/PI3K molecular network deregulation in SCCHN
The EGFR pathway is commonly activated in SCCHN and represents the most validated molecular therapeutic target to date. Grandis et al. [47] first demonstrated that EGFR overexpression is a very common molecular alteration in SCCHN. The magnitude of its expression is associated with inferior survival in OSCC [48] . EGFR activation triggers a signal transduction cascade that includes activation of the Ras/Raf/mitogen-activated protein kinase (MAPK) and PI3K/Akt signaling pathways [2, 8, 14] . Cetuximab is a chimeric IgG1-human monoclonal antibody directed against the extracellular domain of EGFR, blocking thus ligand binding to the receptor and has been approved by regulatory authorities for the treatment of SCCHN [3] . However, cetuximab has an objective response rate of only 13% when used as a single agent [49] . Resistance to EGFR-targeted therapy hinders successful treatment and the identification of resistance mechanisms remains an active research area in SCCHN. These mechanisms of resistance may include epithelial to mesenchymal transition and activation of alternative or downstream pathways [50, 51] . Possible ways to overcome resistance to anti-EGFR agents in SCCHN include (but are not restricted to) the inhibition of other redundant receptor tyrosine kinases (e.g. HER2 and MET), reduction or abrogation of nuclear functions of EGFR, disruption of cellular trafficking by inhibition of histone deacetylase and inhibition of downstream mediators in the EGFR signaling stream (e.g. aurora-kinase inhibitors, STAT decoys, Mek inhibitors) [15, 52] . Analysis of exome sequencing data of 151 head and neck cancer specimens focusing on the EGFR/RAS/MAPK signaling pathway revealed that 8% of tumors contained mutations in the RAS/MAPK component (Erk1, Erk2, MEK1, MEK2, RAF1, ARAF, BRAF, HRAS, KRAS, NRAS, SHC1, SHC2, SHC3 and GRB2) of the pathway [5] . Furthermore, an extended analysis of whole-exome sequencing data, from 190 SCCHN specimens revealed that the MAPK mutational profile is characterized primarily by HRAS mutations (Table 1) with an average somatic mutation rate of 6.21%, whereas KRAS mutations are rare in SCCHN (<1%) [5] [6] [7] [8] . These findings were consistent with results from the recently reported TCGA analysis [10] , which identified HRAS mutations in 4.0% of the 306 samples studied. Figure 1) . PI3K, on the other hand, is involved in diverse cellular signaling pathways including proliferation, differentiation, migration, trafficking and glucose homeostasis. Many receptor tyrosine kinases such as EGFR, ErbB3, Met, VEGFR and G-protein-coupled receptors may activate PI3K after ligand binding. PI3K activation may also occur via PIK3CA mutations or PTEN loss (Figure 1 ). Previous genomic studies had reported a high incidence (∼75%) of activating genetic alterations, mainly copy-number gain, in components of the PI3K pathway in SCCHN [53] . In their recent whole-exome sequencing analysis, Lui et al. [5] identified components of the PI3K pathway (PIK3CA, PIK3AP1, PIK3C2A, PIK3C2B, PIK3C2G, PIK3CB, PIK3CD, PIK3CG, PIK3IP1, PIK3R1/2/3/4/5/6, AKT1/2/3, mTOR, PTEN, PDK1, TSC1/2, RICTOR and RPTOR) as frequently mutated in SCCHN (30.5%). In the same study [5] , the authors reported that PI3K pathway-mutated SCCHN tumors harbored a significantly higher rate of mutations in all known cancer genes and that all tumors with concurrent mutation of multiple PI3K pathway genes were in advanced clinical stage at diagnosis, suggesting a significant contribution of PI3K pathway aberrations in SCCHN progression. Overall, the recent wholeexome analysis of 190 cancer specimens [5] [6] [7] [8] showed that PIK3CA is one of the most commonly mutated genes in SCCHN-with an average mutational rate of 10.53% (Table 1) . Interestingly, PIK3CA gene copy-number analysis, conducted in a subgroup of 83 samples of the same cohort, showed that 18% of tumor specimens harbored PIK3CA gene copy amplification [5] . It is worth noting that based on TCGA data, the reported incidence of PIK3CA mutations in 306 head and neck cancer specimens rose up to 20.6%, which is significantly higher compared with the aforementioned average mutational rate (10.53%) of the first deep sequencing studies in head and neck cancer [5] [6] [7] [8] .
The genomic landscape of SCCHN is also characterized by chromosomal deletions of the PTEN gene locus. Previous studies had reported LOH of the tumor suppressor PTEN in SCCHN, by PCR-based microsatellite analysis in relatively small patient cohorts [54, 55] . Lui et al. [5] , using an Affymetrix® Genome-Wide Human SNP Array 6.0 platform in a cohort of 45 SCCHN tumors that had been analyzed by whole-exome sequencing, showed that PTEN gene copy loss was found in 8.16% of cases. In addition to these chromosomal alterations, somatic mutations of the PTEN gene were relatively frequent with an average mutational rate of 5.45% [5] ( Table 1) .
The implication of the Ras/PI3K/Akt/mTOR pathway deregulation in SCCHN carcinogenesis and in resistance to EGFR inhibition justifies the use of molecular inhibitors for targeting components of this pathway in early clinical trials (Table 2) . Various approaches to inhibit Ras signaling have not been successful in clinical trials possibly due to secondary alterations in other Ras pathway effectors. Reovirus type 3 Dearing (RT3D) (Reolysin, Oncolytics Biotech) exerts selective toxicity against cells with an activated MAPK pathway either through RAS mutation or upregulated EGFR signaling. A randomized phase II study comparing carboplatin, paclitaxel and reolysin versus the same chemotherapy doublet with placebo in second-line therapy of patients with recurrent/metastatic SCCHN has been completed and results are awaited (NCT01166542). A phase I/II study tests combined Mek and Akt inhibition in a variety of solid tumors including SCCHN (NCT01476137). Cetuximab and Lapatinib (HER1/HER2 inhibitor) combination is being assessed in a phase I clinical trial in SCCHN, colon and lung cancer (NCT01184482). MK2206, an Akt inhibitor, was assessed in a phase II trial in recurrent/metastatic SCCHN (NCT013 49933) but is no longer under clinical development (Table 2) .
Three classes of PI3K inhibitors are currently being tested in clinical trials in SCCHN patients: (i) Combined inhibitors of PI3K and mTOR such as NVP-BEZ235 and GDC-0980. SCCHN orthotopic tumor xenografts with PIK3CA mutations were exquisitely sensitive to NVP-BEZ235 [56] . GDC-0980 is currently being investigated in a phase I study in refractory solid tumors (NCT00854152) while development of NPV-BEZ235 has been halted because of difficulties in reformulation of the drug. (ii) Pan-Class I PI3K inhibitors. Examples include NVP-BKM120, GDC-0941 and PX-866. The PI3K inhibitor PX-866 (LC Laboratories, Boston, MA) was used as a successful treatment approach in patient tumor xenografts in two cases of tumors harboring inactivating NOTCH1 mutations [57] . NVP-BKM120 is currently being evaluated in relapsed SCCHN in a phase II study (NCT01737450), while PX-866 is tested in combination with cetuximab (NCT01252628) and with docetaxel (NCT01204099); (iii) alpha-specific ( p110alpha-specific) inhibitors such as NVP-BYL719, which is currently in phase II testing for SCCHN in combination with cetuximab (NCT0160 2315) ( Table 2) . It remains uncertain which type of PI3K inhibitors is most promising for SCCHN, as well as which drug to potentially combine with PI3K inhibitors, and which biomarkers may harbor predictive value. Nevertheless, the abundance of genetic aberrations in the PI3K pathway combined with data derived from early clinical trials [58] suggests that PI3K is a promising target for SCCHN. As a proof of concept, early-phase clinical trial results showed that patients with various solid tumors harboring a PIK3CA 'hotspot' mutation (H1047R) were responsive to PI3K pathway inhibitors [59] and that mTORbased targeted therapy may be more effective in SCCHN tumors harboring PIK3CA mutation and/or PTEN loss [57] . mTOR is activated by Akt, directly or indirectly, promoting cell proliferation and survival [60] . A phase II study (TEMHEAD) evaluated efficacy and toxicity of the mTOR inhibitor temsirolimus in refractory SCCHN failing platinum-based chemotherapy and cetuximab: the primary end point was PFS at 12 weeks >20% and 40% of the patients reached this objective. Fifty-five percent of the patients attained stable disease while no objective responses were reported [61] .
mutations that affect squamous differentiation in head and neck epithelium
The Notch signaling pathway controls cell fate decisions through interactions between neighboring cells by positively or negatively affecting, in a context-dependent fashion, processes of proliferation and differentiation [62] . In keratinocytes, increased Notch activity restricts their proliferative potential and promotes differentiation [63, 64] , whereas loss of Notch1 function promotes carcinogenesis [57, 65] . In mouse and human epidermis, jagged1/2, Notch1 and Notch2 are co-expressed in differentiating keratinocytes of suprabasal layers coordinating the keratinocyte differentiation program. In mammals, each of the four Notch receptors (Notch1-4) is synthesized as a precursor that is proteolytically processed to a cell membrane heterodimer ( Figure 1 ). Two additional cleavages in response to ligand interaction (Dll1, Dll3, Dll4, Jag1 or Jag2) release the Notch intracellular domain, which translocates to the nucleus and modulates the expression of target genes, predominantly by binding and converting the ubiquitous repressor to a transcriptional activator [66] .
The most impressive finding to emerge from the wholeexome sequencing studies in SCCHN is the discovery of a high incidence of loss-of-function (LOF) mutations within the NOTCH1 gene. More specifically, the average mutational rate of NOTCH1 in first deep sequencing studies in head and neck cancer was found to be 12.67%, whereas the average mutational rate of NOTCH2 and NOTCH3 was 4% [6, 7] (Table 1) . Based on TCGA data, the reported incidence of NOTCH1 mutations in 306 head and neck cancer specimens rose up to 19.3% [10] . The vast majority of NOTCH1 mutations in SCCHN were missense mutations that occurred at or near-identified important receptor domains such as the ligand binding domain (EGF repeats 11, 12 and 13) or the ankyrin domains. In addition, the detected nonsense mutations were predicted to result in truncated Notch1 proteins lacking domains important for transcriptional activity. These data suggest that Notch1 is acting as a tumor suppressor in head and neck epithelium. Notch is an established tumor suppressor in the skin and in chronic myelomonocytic leukemia [30, 67] .
While Notch activation restricts the proliferative potential of keratinocytes and promotes differentiation, p63, a close homolog of the p53 tumor suppressor protein, has been linked to cell fate determination and/or maintenance of self-renewing populations in several epithelial tissues [68] [69] [70] [71] [72] . While downregulated by Notch activation, p63 in turn, counteracts the ability of Notch to restrict growth and promote differentiation, with antagonistic effects on Hes/HERP family members (Hes-1, Hey1, Hey2) of Notch-responsive genes [73, 74] . p63 has also the potential of modulating expression of the Jagged 1 and/or 2 ligands [75, 76] , thereby extending its effects on Notch signaling to neighboring cells. It seems that the existence of this complex negative feedback loop between Notch and p63 controls the balance between keratinocyte self-renewal and differentiation.
Interestingly, TP63 was found to harbor an average mutation rate of 8.5% in the studies by Stransky et al. [5, 8] (Figure 1 ). In addition, TP63 gene copy-number amplification was observed in 26% of tumors in the study by Pickering et al. [8] . Overall, recent deep sequencing data suggest that deregulation of the fine balance between p63 and Notch signaling pathways in head and neck epithelium, either by acquisition of loss of function NOTCH1 mutations or by TP63 genomic alterations, disrupts a stratified squamous differentiation program in precursor cells and abolishes the cell cycle control. Consequently, therapeutic interventions that could re-activate the disrupted Notch pathway might prove a promising clinical approach in the future. Another translational application emerging from the understanding of the role of NOTCH signaling in SCCHN may lie in identifying the pathways that become deregulated after NOTCH inactivation and confer a proliferative and/or a prosurvival advantage.
mutations that affect chromatin-remodeling molecules
Epigenetic changes are mostly the consequence of alterations in chromatin structure, including CpG island hypermethylation and histone modification. The role of epigenetic alterations in cancer development has been the focus of interest in recent years. These epigenetic abnormalities are present in almost all cancers and drive tumor progression. In head and neck cancer, most studies have focused on the analysis of promoter methylation of tumor suppressor genes playing a role in vital cellular mechanisms. Methylation of CCNA1, CYGB and P16 genes has been correlated with clinicopathological parameters in OSCC [77] . In the same malignancy, different levels of methylation have also been reported for the P16, P15, P14, DCC, DAPK, MINT1, MINT2, MINT27 and MINT31 gene promoters [78] . Aberrant methylation of the P14, P15 and P16 gene promoters has been reported in SCCHN [79] , oral precancerous lesions [80] , oral carcinomas [81] [82] [83] and salivary gland carcinomas [84] .
One of the most frequently mutated gene sets identified in the whole-exome sequencing study by Stransky et al. [6] included the histone methyl-transferases MLL2 and EZH2, which are involved in the regulation of chromatin structure and activation of gene transcription (Figure 1 ). More specifically, MLL2 and EZH2 were found mutated in 11% and 5% of cancer specimens, respectively (Table 1 ). In the TCGA analysis, the histone modifier genes MLL2, MLL3 and NSD1 were identified as frequently mutated genes in head and neck cancer with a mutational rate of 17.9%, 7.3% and 10.6%, respectively. However, the reported mutational rate of EZH2 was significantly lower (0.3%) [10] . The majority of the somatic mutations observed in MLL2 and EZH2 were inactivating, indicating that both enzymes are tumor suppressors of significance in head and neck cancer. As an epigenetic process that can potently modify many transcriptional outputs, these mutational events have the potential to change the gene expression of global sets of genes. The observation of chromatin modifier genes being frequently mutated in head and neck cancer strongly highlights the dynamic role of nucleosome in tumorigenesis.
Deciphering the epigenetic machineries has provided new opportunities to develop cancer treatments. The first generation of FDA-approved epigenetic cancer drugs includes inhibitors of DNA methyl-transferases (DNMTs) such as azacitidine and decitabine and histone deacetylases (HDACs), including vorinostat and romidepsin. While clinically effective, there was a lack of understanding how these agents modulate specific epigenetic pathways to provide clinical benefit. The general hypothesis is that targeting epigenetic enzymes in cancer cells would disrupt the transcriptional program, which drives oncogenesis, in order to provide therapeutic benefit. However, since vorinostat and romidepsin inhibit multiple HDACs, it has not been clarified whether disease-specific transcription may be modulated without perturbing the general gene expression program. Therefore, it is unclear whether these broad strategies will ever have a favorable therapeutic index.
An intensive effort from research collaborations focuses on the development of more selective DNMTs and HDACs but the major challenge remains the adoption of a rational patient stratification strategy to best test these therapeutics [85] . However, the identification of LOF mutations of epigenetic proteins adds considerable complexity to the identification of tractable drug targets. The fact that epigenetic processes are often controlled by opposing sets of enzymes or pathways, offers a possible solution to this problem. For example gene silencing induced by the Polycomb group proteins is antagonized by the Trithorax group proteins, which activate transcription [86] . Deacetylases and demethylases reverse the enzymatic reactions mediated by acetyl-transferases and methyl-transferases. Therefore, functional genomic studies to dissect the interplay of epigenetic pathways in clearly defined disease models are required to shed light on how to best modulate those pathways so as to reverse the LOF mutations. Synthetic lethal screens or functional compensation screens will assist in the identification of novel druggable targets.
mutational profile of HPV-driven carcinogenesis
The molecular pathways implicated in neoplastic transformation in HPV-associated SCCHN are clearly distinct from those of the 'classical' tobacco/alcohol-associated disease: mounting preclinical evidence suggests that the integration of DNA from high-risk HPV serotypes into the cellular genome of the host mitigates the expression of the main transcription/replication factor E2F that normally functions as a transcriptional repressor of the E6 and E7 viral oncogenes included in the integrated viral DNA. As a consequence, E6 and E7 oncogenes are continuously expressed in SCCHN cells, promoting DNA replication and degradation of p53 and pRb tumor suppressor proteins [87] .
A universal finding in the exome sequencing studies in SCCHN is that tumors that were negative for HPV DNA had more mutations than did HPV-positive ones: in the study by Aggrawal et al. [7] far fewer genes were mutated per tumor in HPV-associated tumors, compared with those not genetically related to HPV (mean ± 95% CI 4.8 ± 3 versus 20.6 ± 16.7 mutations/Mb, respectively, P < 0.05) ( Table 1 ). Of note, the difference in the number of mutations between HPV-associated and HPV-negative tumors was independent of smoking status [7] . Despite the 5-fold difference in the absolute frequency rates, Stransky et al. [6] reported consistent results, with the mutation rate of HPV-positive tumors being approximately half of that found in HPV-negative SCCHN (mean of 2.28 mutations/Mb compared with 4.83 mutations/Mb, P = 0.004). These data suggest that in HPV-negative tumors, the absence of the oncogenic effect of HPV requires the accumulation of multiple genetic aberrations with synergistic effect in order to trigger neoplastic transformation.
Of particular importance is the inverse correlation between HPV status, as determined by DNA sequencing, and TP53 mutation status that has been previously reported [11, 12] . Indeed, although HPV16 and mutated TP53 may coexist in a subset of SCCHN, HPV16 and disruptive TP53 mutations seem to be nonoverlapping events. The recent exome sequencing studies confirmed this observation, with Aggrawal et al. [7] reporting the presence of inactivating TP53 mutations in 78% of the HPV-negative tumors but in none (0%) of the HPV-associated ones. The predominant role of HPV serotype 16 infection in nonsmoking patients with tumors of the oropharynx which are 'wild type' for the tumor suppressor genes TP16, RB and TP53 was confirmed by the TCGA analysis [10] . It is worth noting that in their whole-exome sequencing study, Lui et al. [5] were able to identify a subset of HPV-positive SCCHN tumors (3 of 15, 20%), where PIK3CA or PIK3R1 was the only mutated gene found, suggesting that the tumor progression in this subset of HPV-positive tumors is driven, at least in part, by mutations in the PI3K pathway, along with the TP53 and RB functional loss due to the viral oncoproteins. However, the number of HPVpositive SCCHN tumors in their cohort was relatively small (15 cases) and the observed association between HPV status and PIK3CA/PIK3R1 mutations needs to be validated in a large cohort study.
Taken altogether, these results suggest that viral infection by HPV defines a distinct molecular subset of SCCHN tumors in which the major driver is the oncogenic potential of the viral DNA itself. In HPV-negative tumors, on the other hand, gradual acquisition of mutations in genes regulating critical pathways is a prerequisite to provoke neoplastic transformation, as reflected by the high overall mutation load in those tumors. These observations have direct clinical impact, since they provide a possible explanation for the more favorable clinical outcome of HPVrelated tumors, when compared with HPV-negative ones, and at the same time, point to different therapeutic strategies in the two entities: in HPV-related tumors, immunotherapy (e.g. with vaccines) possesses a strong theoretical rationale in terms of prevention, whereas in HPV-negative/TP53-mutated tumors strategies targeting the mutated tumor suppressor gene may prove more successful.
are all genetic events in SCCHN targetable?
Although genomic alterations in SCCHN are dominated by loss of function of tumor suppressor genes, which are generally difficult to target, a considerable proportion of tumors in all exome sequencing studies [5] [6] [7] [8] [9] [10] harbored at least one genetic event in a molecular pathway for which a targeted agent is in early or late clinical development ( Table 2 ). For example in the study [8] focusing on OSCC, 76 targetable genes with at least one sample containing a copy gain with increased expression or activating mutations were identified, among which 45 were targets for agents already approved in cancer. These findings are clinically crucial because they raise the possibility that future treatment strategy in SCCHN may not rely solely on 'synthetic lethality' approaches directed against tumor suppressor genes as initially suggested [6, 7] , but that selective targeting of the main oncogene drivers may also be of therapeutic relevance. Validation of these candidate oncogenic events in functional studies is required; however, because it is possible that many of those events will not prove useful in the management of patients with SCCHN.
Molecular pathways with genetic aberrations for which approved targeted agents are currently available include the EGFR-mediated pathway, the VEGFR-mediated pathway, the MAPK-mediated pathway and the PI3K/Akt/mTOR pathway. Candidates with therapeutics already in clinical trials include aurora-family kinases, src-family kinases and anaplastic lymphoma kinases. All those genes may represent novel therapeutic avenues in SCCHN and several early clinical trials are currently ongoing (Table 2) . On the other hand, a number of significantly mutated genes in SCCHN are not currently targetable, such as FAT1 and CASP8 (mutated in 22.9% and 8.6% of cases, respectively, in TCGA analysis [10] ).
Novel molecular targets with potential future clinical impact also include HER2 [88] and the fibroblast growth factor receptors (FGFR) 1, 2 and 3 that represent components of autocrine signaling networks in SCCHN [89] and may be related to resistance to antiangiogenic treatment [90] . Insulin-like growth factor 1 receptor (IGF1R) is another appealing target in SCCHN [91] , due to the established cross-talk with EGFR [92] ; IGF1R immunohistochemical expression has been shown to be predictive of gefitinib activity in SCCHN patients receiving postoperative chemoradiation [93] and represents an independent predictor for relapse and survival in patients with operable, squamous-cell laryngeal cancer [94] . Finally, the role of the human leukocyte antigen-G (HLA-G) in tumor cells is becoming increasingly important since it may facilitate immunosurveillance escape: in this context, recent data suggest a possible role for HLA-G polymorphisms in the carcinogenesis and progression of nasopharyngeal cancer [95] . Notably, mutations in HLA-A were reported in 3.2% among 279 cases in the TCGA analysis [10] .
clinical impact and future therapeutic challenges
Early cancer genome analysis has already led to new targets for cancer therapy and has provided new insights into the relationship of specific genetic events and clinical response, or diagnosis and prognosis. High-throughput sequencing technology now provides the means to conduct comprehensive analysis of all somatic alterations in the cancer genome. Interpretation of the large amount of data that emerge from these genome-scale investigations requires their efficient validation and the biological characterization of mutations. Cross-check evaluation of candidate mutations should include detection of the mutation in an independent (validation) set of tumors and a robust biological rational behind the mutation that may explain why the activation (or the loss of function) of the corresponding protein or molecular pathway may be a causative event in the process of carcinogenesis. In this direction, researchers should validate that the identified nucleotide changes do not represent germline-inherited sequence variants [single nucleotide polymorphisms (SNPs)]. Expression of corresponding cDNAs harboring the identified mutations in human cancer cell lines or primary culture cells should be combined with protein functional assays in an effort to investigate whether these mutations are responsible for disease pathogenesis (driver mutations) or have been generated as the consequence of genomic instability, but without obvious advantage to the cancerous cells (benign mutations). An illustration of the proposed process for detection, validation and clinical integration of mutations representing biomarkers with potential clinical application in SCCHN is provided in Figure 2 .
Established human cancer cell lines have been used extensively in functional validation assays of identified mutations due to their ease of manipulation and, although such systems only partially model the more complex biological features of cancers in vivo, they have been proven useful in defining signaling pathways, and establishing pharmacogenomic relationships. A major challenge to the optimal use of these established cancer cell line panels has been the lack of a complete atlas of the genetic alterations in those cells. In this context, it is worth noting that in many cases, in silico analysis using bioinformatic tools can also predict the possible impact of an amino acid substitution on the structure and function of a protein using evolutionary conservation data and therefore can predict whether an identified mutation is 'benign' or not [96, 97] .
Acquisition of gene expression profile using microarrays is also one useful tool to measure the functional consequence of genomic alterations identified in transcription factors or proteins that regulate the chromatin remodeling or promoter methylation. Furthermore, gene expression data combined with luciferase reporter assays and chromatin immunoprecipitation analysis can provide a more detailed profile for the functional significance of identified mutations in proteins that regulate transcription.
Future efforts will need to analyze the genetic heterogeneity within tumors. A future challenge is to explore patterns of molecular heterogeneity on the single-cell level to determine how such heterogeneity affects tumor biology and response to treatment. Recent large-scale studies performing whole-exome sequencing in more than 300 patients with SCCHN, identified mutations in tumor suppressor genes and oncogenes, able to evoke deregulation of molecular pathways critical for genome integrity and squamous differentiation and may represent the dominant genetic events in SCCHN carcinogenesis. High-throughput analysis of human head and neck cancer will soon generate comprehensive lists of genomic and epigenomic alterations present in diverse tumor samples. The integration of those clinicogenomic characterization efforts-both structural and functional-promises to provide a thorough understanding of the somatic alterations that program cancer initiation, maintenance and progression. 
